PMA supplement
P010015 S168: CONSULTA CRT-P, C4TR01, SYNCRA CRT-P C2TR01
FDA PMA supplement · 30-Day Notice · Medtronic, Inc.
Key facts
| Original PMA | P010015 |
|---|---|
| Supplement number | S168 |
| Supplement type | 30-Day Notice |
| Trade name | CONSULTA CRT-P, C4TR01, SYNCRA CRT-P C2TR01 |
| Generic name | Drug eluting permanent left ventricular (lv) pacemaker electrode |
| Applicant | Medtronic, Inc. |
| Product code | OJX |
| Received date | Jul 25, 2012 |
| Decision date | Aug 17, 2012 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: